Elizabeth Griffiths

Hematologic Oncology
Buffalo Spree Top Doctor 2024

Dr. Griffiths is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2024

Cancers Treated:

Specializing In:

Inherited and Acquired Bone Marrow Failure Syndromes (including Aplastic Anemia) Myeloproliferative diseases (MPD) Hematologic Oncology

Research Interests:

Immuno-Epigenetics Early Phase Clinical Trials Inherited Myeloid Cancer Predisposition Syndromes Translational Medicine

About Elizabeth Griffiths


I joined Roswell Park’s Leukemia Service in the Department of Medicine in March 2010. I treat patients with blood disorders, specifically acute myeloid and lymphoid leukemias, as well as bone marrow failure syndromes such as aplastic anemia and myelodysplastic syndrome (MDS). The MDS Foundation recognizes our MDS program as an MDS Center of Excellence. I am an Associate Professor at the State University of New York (SUNY) at Buffalo and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics, Translational Medicine and Immunology.

I joined Roswell Park following completion of a five-year medical oncology and hematology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, MD, where I also completed my internal medicine residency, in 2005. I completed my medical training at the University of North Carolina School of Medicine, Chapel Hill, NC, in 2002, earning my degree as a Doctor of Medicine with Distinction.

I am board certified in hematology, oncology and internal medicine and hold medical licenses in New York and Maryland. I am a member of multiple professional organizations, including the American Society of Hematology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer and the American Society of Oncology.

My research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. We have examined how HMAs can cause re-expression of proteins in cancer cells that can be targeted by the immune system. I have authored/co-authored more than 50 peer-reviewed publications.


Roswell Park Comprehensive Cancer Center
  • Associate Professor
  • Director of MDS
  • Clinical Disease Team Leader
  • Director for Liquid Tumor, Center for Early Phase Clinical Trials
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Associate Professor
  • Department of Medicine


Education and Training:

  • 2002 - University of North Carolina School of Medicine, Chapel Hill, NC


  • 2005 - Internal Medicine - Johns Hopkins Hospital, Baltimore, MD


  • 2010 - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD

Board Certification:

  • 2008 - Hematology - American Board of Internal Medicine
  • 2009 - Oncology - American Board of Internal Medicine
  • 2005 - Internal Medicine - American Board of Internal Medicine

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed
  • Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019;6(6):e317-e327.
  • Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.Blood Adv. 2018 Nov 13;2(21):3070-3080.
  • El Chaer F, Ali OM, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Wong J, Yared JA, Griffiths EA, Emadi A. Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. Am J Hematol. 2019 Jan;94(1):E7-E8.
  • Griffiths EA, Srivastava P*, Matsuzaki J, Brumberger Z*, Wang ES, Kocent J, Miller A, Paluch BE*, Lutgen-Dunckley LE, Martens BL, Odunsi K, Karpf AR, Nemeth MJ. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with High-Grade Myeloid Malignancy. Clinical Cancer Research. 2018;24:1019-1029.
  • Krönke J, Fink EC, Hollenbach PW, MacBeth K, Hurst EN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS. Nature. 2015;523(7559):183-8.